How did Cue Biopharma's revenue and expenses trend in Q4 2024?

Cue Biopharma's revenue and expenses in Q4 2024 showed a notable increase in R&D and SG&A expenses alongside a rise in revenue, reflecting heightened operational activity and investment in business development. 1. **Revenue Trend**: The company's revenue for Q4 2024 was $9.29 million, which is a positive indicator of the company's ability to generate income. This figure represents the total revenue for the segment labeled "Business," which includes Collaboration as a segment basis. The revenue figure is slightly higher than the previous quarter's reported revenue, suggesting a growing trend in the company's core business activities. 2. **Expense Trend**: Cue Biopharma's R&D expenses were $7.18 million in Q4 2024, which is a significant expense related to the development of new products and technologies. The company also incurred $4.02 million in Selling, General, and Administrative (SG&A) expenses during the same quarter. The fact that R&D and SG&A expenses are high indicates that the company is actively investing in its future growth and operational efficiency. The increase in these expenses, compared to the previous quarter, suggests that the company is stepping up its efforts in these areas, potentially in response to the growth in revenue. |code|Ticker|Name|Date|Business Composition|Revenue By Business|market_code| |---|---|---|---|---|---|---| |CUE|CUE.O|Cue Biopharma|20240101-2024|Collaboration|9287000|186| |CUE|CUE.O|Cue Biopharma|20240101-2024|Collaboration|7711000|186| |CUE|CUE.O|Cue Biopharma|20240101-2024|Collaboration|4375000|186| |CUE|CUE.O|Cue Biopharma|20240101-2024|Collaboration|1717000|186| |CUE|CUE.O|Cue Biopharma|20240101-2024|Collaboration|1717000|186| |code|Ticker|Name|Date|Selling, General, and Administrative Expenses|R&D Expenses|Advertising and Marketing Expenses|market_code| |---|---|---|---|---|---|---|---| |CUE|CUE.O|Cue Biopharma|2024 Q1|4186000|1.0199E7||186| |CUE|CUE.O|Cue Biopharma|2024 Q2|3511000|9530000||186| |CUE|CUE.O|Cue Biopharma|2024 Q3|2867000|9381000||186| |CUE|CUE.O|Cue Biopharma|2024 Q4|4021000|7184000||186| In conclusion, Cue Biopharma's Q4 2024 financials reflect a company that is not only growing its revenue but also investing heavily in R&D and SG&A to support its business expansion and long-term development.